Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds
Epistaxis is the most prevalent clinical symptom in Hereditary Haemorrhagic Telangiectasia (HHT), causing anaemia and decreasing the quality of life (QOL). Since 2013, in Hospital Universitario Fundación Alcorcón, more than 150 HHT patients have been treated by nose sclerotherapy on demand. This stu...
Main Authors: | Sol Marcos, Luisa María Botella, Virginia Albiñana, Agustina Arbia, Anna María de Rosales |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/17/3845 |
Similar Items
-
Tacrolimus as a Promising Drug for Epistaxis and Gastrointestinal Bleeding in HHT
by: Paloma Álvarez-Hernández, et al.
Published: (2023-11-01) -
3% Polidocanol sclerotherapy for pyogenic granuloma: Efficacy and safety analysis
by: Ajay J Deshpande, et al.
Published: (2022-01-01) -
Sclerotherapy using polidocanol foam for a giant splenic cyst
by: Hiraku Funakoshi, MD, MPH, PhD, et al.
Published: (2020-09-01) -
Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)
by: John M. Lee, et al.
Published: (2019-10-01) -
Intralesional Sclerotherapy with Polidocanol in the Management of Head and Neck Vascular Lesions
by: Arindam Das, et al.
Published: (2016-12-01)